ViroPharma is rare among biotechnology companies. We are in the enviable position of having a strong and growing balance sheet; a promising pipeline with novel drugs targeting great unmet medical needs and serious diseases; two FDA approved products that are today saving and improving lives: Vancocin® which treats two significant bacterial infections of the lower gastrointestinal tract; and Cinryze™ (C1 Esterase Inhibitor [Human]) which is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE); and an excellent and experienced team throughout our global organization.
We will continue to leverage our clinical and business development expertise and our balance sheet to expeditiously develop our current pipeline, maximize the opportunities for success of our marketed products, and bring new product opportunities into the company. Through our efforts, we believe that we will be successful in providing great value to our shareholders, our employees, the patients we seek to treat, and the physicians who treat them. At ViroPharma, we believe that the work we are doing today throughout our organization will enable us to reach our goals.
Contact Investor Relations
ViroPharma, Inc. Investor Relations 730 Stockton Drive Exton, PA 19341-1171 United States Phone: 1.610.458.7300 SIC Code:2834
Vincent J. Milano, President, CEO & Chairman of the Board of Directors
Vincent Milano is ViroPharma's President and Chief Executive Officer, and Chairman of the Board of Directors as of March 2008. He joined the company in 1996 and served as vice president, chief financial officer, and treasurer from 1997 to 2006. In 2006, he assumed the role of vice president, chief financial officer and chief operating officer. Mr. Milano has been instrumental in building ViroPharma, including leading efforts in raising nearly $900 million in capital and the acquisition of Vancocin® from Eli Lilly and Company. He has played a critical role in all business development and investor relations activities of the company, and has contributed significantly to establishing the strategic direction of the company. Prior to joining ViroPharma, he was with KPMG LLP, independent certified public accountants, where he served as senior manager. Mr. Milano received his bachelor of science degree in accounting from Rider College.
Daniel B. Soland, Vice President, COO
Daniel B. Soland is ViroPharma's Vice President and Chief Operating Officer as of March 2008. He joined ViroPharma in November 2006 as Vice President and Chief Commercial Officer following his previous post as President of Chiron Vaccines. At Chiron, Soland was most recently responsible for managing the vaccine division to annual sales of $1 billion. Prior to Chiron, he was the president and chief executive officer of Epigenesis Pharmaceuticals, a privately held biopharmaceutical company engaged in developing drugs for use in asthma, COPD and allergic rhinitis. Prior to that, Mr. Soland spent nine years with GlaxoSmithKline as the vice president and director of worldwide marketing operations, and five years as their vice president and director of the U.S. vaccines business unit. Mr. Soland holds a Bachelor of Science degree in pharmacy from the University of Iowa, in Iowa City, IA.
Robert G. Pietrusko, Vice President, Global Regulatory Affairs and Quality
Dr. Pietrusko joined ViroPharma in 2007 from his previous post as senior vice president of worldwide regulatory affairs for Millennium Pharmaceuticals, Inc., where was most recently responsible for the global regulatory affairs function and strategy. He was instrumental in the approval of Millennium's products, including the accelerated approval and worldwide regulatory strategy for Velcade, a product approved in over 75 countries worldwide. Prior to Millennium, he spent 19 years at GlaxoSmithKline, culminating in his tenure as vice president and director, anti-infective and antiviral therapeutic areas, U.S. regulatory affairs, where he led the anti-infective and antiviral regulatory groups. During his tenure at GlaxoSmithKline, he was instrumental in approvals for products including Havrix, Augmentin® XR and ES (amoxicillin/clavulanate potassium) for bacterial sinusitis and community-acquired pneumonia, and Infanrix® (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed). Dr. Pietrusko has directed the submission of more than 20 NDAs, sNDAs and BLAs to the U.S. Food and Drug Administration (FDA) including antibiotics, anti-virals, vaccines, oncologics, cardiovascular products, pulmonary products and anti inflammatory compounds. He has been directly responsible for organizing and leading eight FDA Advisory Committee presentations. Dr. Pietrusko holds a Bachelor of Science degree in biology and a Bachelors of Pharmacy degree from Rutgers University, and a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Science. Dr. Pietrusko is the author of 52 scientific publications.
Charles A. Rowland, Jr., Vice President & Chief Financial Officer
Charles A. Rowland Jr., CPA, MBA, is ViroPharma's Vice President and Chief Financial Officer. He has 28 years of diversified experience across a broad field of financial areas. Mr. Rowland is responsible for all areas of finance and accounting, including financial reporting, tax, treasury, and strategic financial planning. Most recently, he was the executive vice president and chief financial officer for Endo Pharmaceuticals, as well serving for a period as co-interim chief executive officer. At Endo, Mr. Rowland drove the strategic planning process through two successive chief executive officers. He also led the design and implementation of the company's mid and long-term strategy. Prior to joining Endo, Mr. Rowland spent three years as senior vice president, chief financial officer for Biovail Pharmacueticals, where he directed all financial activities for the company including tax, treasury, accounting, financial analysis, investor relations as well as all aspects of information technology. Mr. Rowland previously held positions of increasing responsibility at Breakaway Technologies, Pharmacia, Novartis and Bristol-Myers Squibb Company. He holds a Bachelors of Science in accounting from St. Joseph's University, and a Master of Business Administration degree from the Rutgers University.
Colin Broom, M.D., Vice President, Chief Scientific Officer
Colin Broom, M.D. has served as Vice President, Chief Scientific Officer of ViroPharma since May 2004. From 2000 until 2003 Dr. Broom served as vice president of clinical development and medical affairs, Europe, for Amgen. From 1998 to 1999, Dr. Broom served as senior vice president of global clinical development for Hoechst Marion Roussel, now Aventis. From 1984 through 1998, Dr. Broom was with Glaxo and then SmithKline Beecham, where he held positions of increasing seniority in clinical pharmacology in Europe before moving to the US to head global oncology and subsequently becoming Vice President of CNS/GI. Dr. Broom holds a Bachelor of Science degree in pharmacology from University College in London, and a Bachelor of Medicine and Bachelor of Surgery degree from St. George's Hospital Medical School. Dr. Broom is a Member of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine of the UK Colleges of Physicians.
Thomas F. Doyle, Vice President, Strategic Initiatives
Thomas F. Doyle is ViroPharma's Vice President, Strategic Initiatives as of January 2008; he previously served as Vice President, General Counsel of ViroPharma since November 1997, as Secretary since November 1997, as Secretary since February 1997 and as Executive Director, Counsel since joining ViroPharma in November 1996. From 1990 until 1996, Mr. Doyle was a corporate attorney with the law firm of Pepper, Hamilton LLP. Mr. Doyle received his J.D. from Temple University School of Law. Prior to attending Temple University, Mr. Doyle was a Certified Public Accountant. Mr. Doyle received his B.S. in Accounting from Mt. St. Mary's College.
Robert C. Fletcher, Vice President, Business Development & Project Management
Robert C. Fletcher is our Vice President, Business Development and Project Management. Mr. Fletcher joined ViroPharma in 2001 as a project leader, and has since held roles of increasing seniority during his tenure in the areas of business development and project management. Prior to joining ViroPharma, Mr. Fletcher held multiple roles of escalating responsibility at SmithKline Beecham Pharmaceuticals/GlaxoSmithKline, Becton-Dickinson and Company, Zynaxis Inc./Intracell Corporation, and Centocor Corporation. He holds both a master of science degree and a bachelor of arts degree in biology from Wake Forest University.
J. Peter Wolf Esq., Vice President, General Counsel & Secretary
J. Peter Wolf has served as Vice President, General Counsel, and Secretary since January 1, 2008 and prior thereto served as Associate General Counsel. Prior to joining ViroPharma, Mr. Wolf was a corporate attorney at private law firms from 1995 to 2004. Mr. Wolf received his J.D. from the George Washington University National Law Center and his Bachelor of Arts from the University of Delaware.